NIH R01 · 2024
Galectin-3: A mediator of vascular remodeling in pulmonary arterial hypertension
PROJECT SUMMARY Pulmonary Arterial Hypertension (PAH) is a progressively debilitating and eventually lethal disease, whereby only the symptoms are treated by current therapeutics. A defining characteristic of PAH is the excessive cellular proliferation and remodeling of pulmonary arteries (PA) that results in increased vascular resistance and stiffness, and eventually failure of the right ventricle and death. PAH has a survival time of less than five-years post diagnosis, and current treatment strategies are self-limiting in that they do not sufficiently prolong survival time or reverse the pathologic vascular remodeling. In the previous funding period we established an important role for…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.